ptgis Antibody

What is PTGIS and why is it important in research applications?

PTGIS (Prostaglandin I2 Prostacyclin Synthase) is an enzyme responsible for catalyzing the conversion of prostaglandin H2 to prostacyclin (PGI2). It plays critical roles in various physiological functions, particularly in the cardiovascular system where it regulates processes like angiogenesis . PTGIS has gained research significance due to its differential expression in multiple diseases including pulmonary hypertension (PAH), hepatic fibrosis, and various cancer types . Recent studies have demonstrated that PTGIS is significantly downregulated in at least 17 cancer types, including colorectal cancer, suggesting its potential role as a biomarker or therapeutic target . When selecting a PTGIS antibody for research, consideration should be given to the specific isoforms and domains you want to target based on your research questions, as different antibodies recognize distinct epitopes within the PTGIS protein.

Which experimental methods are optimal for detecting PTGIS expression in tissue samples?

Multiple complementary methods can be employed for detecting PTGIS expression in tissue samples:

Immunohistochemistry (IHC): This technique provides spatial information about PTGIS expression within tissue architecture. For optimal results, tissue sections should first be fixed in 10% neutral buffered formalin, embedded in paraffin, and subjected to antigen retrieval through microwaving in citric buffer for approximately 15 minutes . To reduce background staining, sections should be treated with 0.3% hydrogen peroxide and blocked with 5% BSA before overnight incubation with primary PTGIS antibody (recommended dilution 1:50) . Signal visualization is typically achieved using 3,3-diaminobenzidine tetrahydrochloride (DAB) staining.

Western Blotting: This technique allows for semi-quantitative analysis of PTGIS protein expression. Cells should be lysed with RIPA buffer, and protein concentration determined via BCA assay. Approximately 20 μg of protein should be loaded for electrophoresis and transferred to PVDF membranes . PTGIS antibodies should be used at appropriate dilutions (typically 1:1000), with detection via HRP-labeled secondary antibodies and enhanced chemiluminescence .

RT-qPCR: This provides quantitative measurements of PTGIS mRNA expression and is frequently used alongside protein detection methods to confirm expression changes at the transcriptional level .

What control samples should be included when validating PTGIS antibodies?

When validating PTGIS antibodies, several controls should be incorporated to ensure specificity and reliability:

Positive Controls: Include tissue or cell types known to express PTGIS at detectable levels. Studies have shown that normal colorectal cells (such as FHC) express PTGIS at higher levels than colorectal cancer cell lines (such as SW480 and HCT8) .

Negative Controls: Include samples where primary antibody is omitted or replaced with non-specific IgG from the same host species as the primary antibody.

Knockdown/Knockout Controls: When possible, include samples where PTGIS expression has been silenced through siRNA or CRISPR-Cas9 technology. PTGIS-RNAi has been successfully used to silence PTGIS expression in certain cell types and can serve as an excellent specificity control .

Overexpression Controls: Cell lines transfected with PTGIS overexpression constructs (such as pEX-2-PTGIS) provide useful positive controls with high expression levels .

These controls collectively allow researchers to confirm antibody specificity and establish appropriate signal thresholds for experimental interpretation.

How can researchers optimize PTGIS antibody performance in Western blotting applications?

Optimizing PTGIS antibody performance in Western blotting requires attention to several technical factors:

Sample Preparation: Total protein should be extracted using RIPA lysate and quantified using a BCA kit. Loading approximately 20 μg of protein per lane typically yields detectable signals for PTGIS .

Blocking Conditions: Use 5% skim milk powder blocking solution for 1 hour at room temperature to reduce non-specific binding .

Antibody Incubation: PTGIS primary antibodies should be used at a dilution ratio of 1:1000 and incubated at 4°C for 14 hours (overnight) for optimal binding .

Washing Protocol: Perform three 5-minute washes with TBST after both primary and secondary antibody incubations to minimize background .

Detection System: Ultra-High Sensitivity ECL kits provide the best results for detecting PTGIS, which may be expressed at relatively low levels in some tissues or cell lines .

Signal Quantification: Use software such as Image J to analyze the relative expression levels of PTGIS, normalizing to appropriate housekeeping proteins such as actin .

How do researchers interpret contradictory PTGIS expression data between transcriptomic and proteomic analyses?

Researchers often encounter discrepancies between PTGIS mRNA and protein levels, which requires careful interpretation:

Methodological Considerations: First verify whether the discrepancies stem from technical issues by repeating experiments with different antibody clones or primer sets. For PTGIS detection, using antibodies targeting different epitopes (such as N-terminal AA 30-61 versus C-terminal AA 472-500) can help confirm expression patterns .

Post-transcriptional Regulation: PTGIS is subject to post-transcriptional regulation, which may explain discrepancies. Assess microRNA profiles that might target PTGIS mRNA or examine RNA stability through actinomycin D chase experiments.

Post-translational Modifications: PTGIS protein function and stability can be affected by post-translational modifications. Phosphorylation states should be examined using phospho-specific antibodies when available.

Epigenetic Regulation: DNA methylation significantly impacts PTGIS expression. Methylation-specific PCR (MSP) assays can determine if epigenetic silencing is occurring despite mRNA transcription .

Protein Turnover Rates: Differences in protein degradation rates can contribute to discrepancies. Pulse-chase experiments with protein synthesis inhibitors can help determine if PTGIS protein has altered stability in your experimental system.

When reporting such discrepancies, researchers should clearly describe all methodological details and discuss potential biological mechanisms rather than dismissing contradictory data.

What are the methodological considerations when studying PTGIS methylation in relation to disease progression?

PTGIS methylation studies require specific methodological considerations:

Genomic Region Selection: Focus methylation analysis on the PTGIS promoter region and first exon, as these regions most strongly correlate with transcriptional silencing. When designing MSP primers, target regions containing multiple CpG islands for highest sensitivity.

Controls and Standards: Always include fully methylated and unmethylated DNA standards as controls. Commercial standards or in vitro methylated DNA using SssI methyltransferase can serve as positive controls.

Correlation with Expression: Simultaneously measure PTGIS mRNA and protein expression to establish the functional consequence of observed methylation patterns. This is particularly important in diseases like liver fibrosis where PTGIS hypermethylation correlates with disease progression .

Treatment with Demethylating Agents: To confirm the causal relationship between methylation and expression, treat cells with demethylating agents such as 5-aza-2'-deoxycytidine and monitor changes in PTGIS expression.

ChIP Assays: Chromatin immunoprecipitation assays using antibodies against methyl-binding proteins or histone modifications can provide additional evidence for the epigenetic regulation of PTGIS in your disease model .

How can researchers design effective PTGIS overexpression and knockdown experiments?

Designing effective PTGIS manipulation experiments requires careful consideration of several factors:

Overexpression Systems:

• Vector Selection: Lentiviral vectors like PLVX-PTGIS-EF1-PURO have demonstrated efficient PTGIS overexpression in experimental systems .

• Primer Design: For PTGIS cloning, primers should include appropriate restriction sites and Kozak sequences for optimal expression. Published primers (Forward: 5-GATCTATTTCCGGTGAATTCGCCACCATGGCTTGGGCCCGCG-3; Reverse: 5-GCGGCCGCTCTAGAACTAGTTCATGGGCGGATGCGGTAG-3) have been successfully used .

• Transfection Verification: Always confirm successful overexpression at both mRNA and protein levels using RT-qPCR and Western blot, respectively .

Knockdown Approaches:

• RNAi Design: PTGIS-RNAi has been effectively used to silence PTGIS expression. Design multiple siRNA sequences targeting different regions of the PTGIS transcript to identify the most effective construct .

• Controls: Include scrambled RNAi controls with similar GC content but no complementarity to any known genes in your experimental organism .

• Validation: Confirm knockdown efficiency at both mRNA (>70% reduction) and protein levels before proceeding with functional studies .

Functional Assessments:

• For cancer studies, assess cell proliferation (EdU incorporation), apoptosis (Annexin-V/PI staining), invasion, and migration capabilities following PTGIS manipulation .

• For fibrosis studies, measure markers of activation (α-SMA, COL1a1) and cell cycle progression (C-myc, CyclinD1) .

• Cell viability should be assessed using methods like CCK8 assay following genetic manipulation .

What are the key considerations when interpreting PTGIS immunohistochemistry data in complex tissue microenvironments?

Interpreting PTGIS immunohistochemistry in complex tissues requires sophisticated analysis:

Cellular Heterogeneity: PTGIS expression varies significantly between cell types within the same tissue. In liver studies, for example, PTGIS shows differential expression between hepatic stellate cells (HSCs), primary hepatocytes, and macrophages . Use double immunofluorescence with cell-type-specific markers (α-SMA for activated HSCs, F4/80 for macrophages) to identify precisely which cells express PTGIS.

Subcellular Localization: PTGIS can show different subcellular localization patterns depending on cell activation state. Document whether staining is predominantly cytoplasmic, perinuclear, or associated with specific organelles.

Quantification Methods: Move beyond subjective scoring by implementing digital image analysis. For PTGIS quantification:

• Use color deconvolution to separate DAB staining from hematoxylin counterstain

• Establish intensity thresholds based on positive and negative controls

• Report both percentage of positive cells and staining intensity

• Consider the use of H-score (percentage of positive cells × intensity) for semi-quantitative analysis

Spatial Context: Analyze PTGIS expression in relation to pathological features (e.g., fibrotic septa, tumor margins) using annotated whole slide images.

Inter-observer Variability: Have multiple trained observers independently score PTGIS staining using standardized criteria to ensure reproducibility.

Technical Limitations: Acknowledge that IHC provides relative rather than absolute quantification of PTGIS. Consider complementing IHC data with absolute quantification methods such as ELISA or mass spectrometry when possible.

How does PTGIS expression influence immune cell infiltration in cancer microenvironments?

Recent research has revealed complex relationships between PTGIS expression and immune cell infiltration in cancer:

Macrophage Polarization: PTGIS expression positively correlates with M2 and M0 macrophage infiltration in both colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ) . This suggests that PTGIS may contribute to creating an immunosuppressive tumor microenvironment, as M2 macrophages typically promote tumor progression through immunosuppressive and pro-angiogenic functions.

T Cell Populations: PTGIS expression negatively correlates with several T cell populations including CD8+ T cells, CD4+ memory activated T cells, and T follicular helper cells in colorectal cancer . This inverse relationship suggests that PTGIS may inhibit effective anti-tumor immunity, as these T cell populations are generally associated with favorable cancer outcomes.

NK Cells: PTGIS expression negatively correlates with activated natural killer (NK) cells , further supporting its potential role in immune evasion mechanisms.

Mast Cells: Interestingly, PTGIS shows a positive correlation with activated mast cells but a negative correlation with resting mast cells . This polarized relationship suggests that PTGIS may contribute to mast cell activation in the tumor microenvironment.

Methodological Approach: To investigate these relationships, researchers should:

• Perform multiplex immunofluorescence to simultaneously visualize PTGIS and immune cell markers

• Utilize single-cell RNA sequencing to better characterize cell-specific expression patterns

• Implement spatial transcriptomics to understand the spatial relationships between PTGIS-expressing cells and immune infiltrates

• Conduct co-culture experiments with PTGIS-manipulated cancer cells and various immune cell populations to establish causative relationships

Understanding these intricate relationships may reveal new therapeutic opportunities targeting PTGIS to enhance anti-tumor immunity.

What are emerging applications for PTGIS antibodies in precision medicine research?

PTGIS antibodies are finding new applications in cutting-edge precision medicine research:

Liquid Biopsy Development: PTGIS antibodies are being explored for the detection of circulating tumor cells (CTCs) and extracellular vesicles, particularly in cancers where PTGIS expression is significantly altered. These approaches could enable non-invasive monitoring of disease progression and treatment response.

Therapeutic Response Prediction: PTGIS expression patterns, detected via immunohistochemistry with validated antibodies, show promise as predictive biomarkers for response to specific therapies. This is particularly relevant in colorectal cancer where PTGIS expression correlates with distinct immune infiltration patterns .

Combined Diagnostic Approaches: Integrating PTGIS immunohistochemistry with DNA methylation analysis provides more comprehensive disease characterization, especially in conditions like liver fibrosis where PTGIS hypermethylation plays a crucial role in pathogenesis .

Targeted Drug Delivery Systems: Antibody-drug conjugates utilizing PTGIS antibodies could potentially deliver therapeutic agents specifically to cells overexpressing PTGIS, though this application requires extensive validation of antibody specificity and internalization kinetics.

Single-Cell Analysis: The application of PTGIS antibodies in single-cell proteomics workflows enables researchers to correlate PTGIS expression with cellular phenotypes at unprecedented resolution, advancing our understanding of heterogeneity in disease progression.